SL Science (SLBT) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
X4 Pharmaceuticals (XFOR) has outperformed SL Science (SLBT) over the past year, losing 20.0% versus a loss of 94.8%. SL Science is the larger company by market cap ($308.4 million vs $306.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLBT | XFOR |
|---|---|---|
| Share price | $0.55 | $3.00 |
| Market cap | $308.42M | $306.34M |
| 1-day change | -3.36% | +1.35% |
| YTD return | -94.78% | -25.00% |
| 1-year return | -94.76% | -20.00% |
| 5-year return | — | -97.79% |
| P/E ratio (TTM) | — | 5.45 |
| EPS (TTM) | $0.00 | $0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.50M |
| Revenue growth (YoY) | — | +150.00% |
| Net income (latest FY) | — | $-79.20M |
| Gross margin | — | 11.43% |
| Operating margin | — | -1336.66% |
| Net margin | — | -1218.45% |
| 52-week high | $14.50 | $4.83 |
| 52-week low | $0.51 | $2.43 |
| Distance from 52-week high | -96.21% | -37.89% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +286.67% |
| Average volume | 67.66K | 877.70K |
| Shares outstanding | 560.76M | 102.11M |
| Employees | 14 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XFOR has outperformed SLBT by 74.8 percentage points over the past year.
About SL Science
SLBT stock →SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 45 employees
SLBT vs XFOR FAQ
Which is bigger, SL Science or X4 Pharmaceuticals?
SL Science (SLBT) is larger, with a market capitalization of $308.42M compared with $306.34M for X4 Pharmaceuticals (XFOR).
Which stock has performed better over the past year, SLBT or XFOR?
XFOR returned -20.00% over the past 12 months, compared with -94.76% for SLBT (price return, excluding dividends). Past performance does not predict future results.
Are SL Science and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.